HRP20030305B9 - Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function - Google Patents

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Info

Publication number
HRP20030305B9
HRP20030305B9 HR20030305A HRP20030305A HRP20030305B9 HR P20030305 B9 HRP20030305 B9 HR P20030305B9 HR 20030305 A HR20030305 A HR 20030305A HR P20030305 A HRP20030305 A HR P20030305A HR P20030305 B9 HRP20030305 B9 HR P20030305B9
Authority
HR
Croatia
Prior art keywords
substituted
aryl
alkyl
heterocyclo
arylalkyl
Prior art date
Application number
HR20030305A
Other languages
English (en)
Croatian (hr)
Inventor
E. Salvati Mark
Aaron Balog James
A. Pickering Dacia
Giese S�ren
Fura Aberra
Li Wenying
N. Patel Ramesh
L. Hanson Ronald
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20030305A2 publication Critical patent/HRP20030305A2/hr
Publication of HRP20030305B1 publication Critical patent/HRP20030305B1/xx
Publication of HRP20030305B9 publication Critical patent/HRP20030305B9/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20030305A 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function HRP20030305B9 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23351900P 2000-09-19 2000-09-19
US28443801P 2001-04-18 2001-04-18
US28473001P 2001-04-18 2001-04-18
PCT/US2001/019655 WO2002024702A1 (en) 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Publications (3)

Publication Number Publication Date
HRP20030305A2 HRP20030305A2 (en) 2005-04-30
HRP20030305B1 HRP20030305B1 (en) 2007-12-31
HRP20030305B9 true HRP20030305B9 (en) 2008-03-31

Family

ID=27398441

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20030305A HRP20030305B9 (en) 2000-09-19 2001-06-20 Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Country Status (36)

Country Link
US (1) US20040176324A1 (cg-RX-API-DMAC7.html)
EP (1) EP1319007B9 (cg-RX-API-DMAC7.html)
JP (1) JP4966477B2 (cg-RX-API-DMAC7.html)
KR (1) KR100765670B1 (cg-RX-API-DMAC7.html)
CN (2) CN1995039A (cg-RX-API-DMAC7.html)
AR (1) AR035340A1 (cg-RX-API-DMAC7.html)
AT (1) ATE318822T1 (cg-RX-API-DMAC7.html)
AU (2) AU6994301A (cg-RX-API-DMAC7.html)
BG (1) BG107675A (cg-RX-API-DMAC7.html)
BR (1) BR0113980A (cg-RX-API-DMAC7.html)
CA (1) CA2423071A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2003780A3 (cg-RX-API-DMAC7.html)
DE (1) DE60117551T2 (cg-RX-API-DMAC7.html)
DK (1) DK1319007T3 (cg-RX-API-DMAC7.html)
EE (1) EE200300108A (cg-RX-API-DMAC7.html)
ES (1) ES2260244T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20074144B (cg-RX-API-DMAC7.html)
HK (1) HK1054230B (cg-RX-API-DMAC7.html)
HR (1) HRP20030305B9 (cg-RX-API-DMAC7.html)
HU (1) HUP0400455A3 (cg-RX-API-DMAC7.html)
IL (1) IL155019A0 (cg-RX-API-DMAC7.html)
IS (1) IS6750A (cg-RX-API-DMAC7.html)
MX (1) MXPA03002412A (cg-RX-API-DMAC7.html)
MY (1) MY138531A (cg-RX-API-DMAC7.html)
NO (1) NO329931B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ524803A (cg-RX-API-DMAC7.html)
PE (1) PE20020729A1 (cg-RX-API-DMAC7.html)
PL (1) PL361707A1 (cg-RX-API-DMAC7.html)
PT (1) PT1319007E (cg-RX-API-DMAC7.html)
SK (1) SK4982003A3 (cg-RX-API-DMAC7.html)
TW (1) TWI305208B (cg-RX-API-DMAC7.html)
UA (1) UA78686C2 (cg-RX-API-DMAC7.html)
UY (1) UY26808A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002024702A1 (cg-RX-API-DMAC7.html)
YU (1) YU20003A (cg-RX-API-DMAC7.html)
ZA (1) ZA200302963B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
TWI263640B (en) * 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1553074B1 (en) 2002-08-12 2014-06-18 Takeda Pharmaceutical Company Limited Fused benzene derivative and use
WO2004110978A2 (en) * 2003-06-10 2004-12-23 Smithkline Beecham Corporation 1-aminonaphthalenes as modulators of androgen, glucocorticoid, mineralocorticoid and progesterone receptors
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
WO2007015567A1 (ja) * 2005-08-01 2007-02-08 Takeda Pharmaceutical Company Limited 環状アミン化合物
US20100004249A1 (en) * 2006-07-11 2010-01-07 Takahiro Matsumoto Bicyclic heterocyclic compound and use thereof
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
EP2455370A1 (en) 2009-07-17 2012-05-23 Shionogi&Co., Ltd. Pharmaceutical product containing lactam or benzene sulfonamide compound
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN112584832A (zh) 2018-06-14 2021-03-30 斯克里普斯研究学院 用于物质使用复发的非肌肉肌球蛋白ii抑制剂
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
WO2022061226A1 (en) * 2020-09-19 2022-03-24 Augusta University Research Institute, Inc. Compositions and methods for inhibiting trem-1
CN115340483A (zh) * 2022-08-31 2022-11-15 南京吉星生物技术开发有限公司 一种萘基吡咯啉二酮化合物及其制备方法与它的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
JPS5046697A (cg-RX-API-DMAC7.html) * 1973-08-20 1975-04-25
US5539126A (en) * 1994-04-20 1996-07-23 Bristol-Myers Squibb Company Method for preparing homochiral maleimide intermediates, via silylation techniques
DK0800519T3 (da) * 1994-12-22 2004-03-01 Ligand Pharm Inc Steroidreceptormodulatorforbindelser og fremgangsmåder
WO1997049709A1 (en) * 1996-06-27 1997-12-31 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP0979407A1 (en) * 1997-04-29 2000-02-16 The Salk Institute For Biological Studies Methods for identifying ligands for nuclear hormone receptors
US7101681B1 (en) * 1997-11-21 2006-09-05 Amgen, Inc. Nuclear hormone receptor drug screens
EP1214325B1 (en) * 1999-09-10 2005-11-09 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
AU2001288213B2 (en) * 2000-06-28 2005-04-14 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use

Also Published As

Publication number Publication date
AU2001269943B2 (en) 2006-11-09
HK1054230B (en) 2006-07-28
JP4966477B2 (ja) 2012-07-04
KR20030028847A (ko) 2003-04-10
CN1307181C (zh) 2007-03-28
BG107675A (bg) 2003-12-31
IL155019A0 (en) 2003-10-31
EP1319007B1 (en) 2006-03-01
CA2423071A1 (en) 2002-03-28
CZ2003780A3 (cs) 2004-01-14
ZA200302963B (en) 2004-07-15
HK1054230A1 (en) 2003-11-21
CN1995039A (zh) 2007-07-11
YU20003A (sh) 2006-03-03
NO20031266L (no) 2003-05-13
TWI305208B (en) 2009-01-11
PE20020729A1 (es) 2002-08-11
PT1319007E (pt) 2006-05-31
JP2004509895A (ja) 2004-04-02
DE60117551T2 (de) 2007-01-18
CN1608069A (zh) 2005-04-20
ES2260244T3 (es) 2006-11-01
DK1319007T3 (da) 2006-06-19
HUP0400455A3 (en) 2007-10-29
NO329931B1 (no) 2011-01-24
HUP0400455A2 (hu) 2004-06-28
DE60117551D1 (de) 2006-04-27
EE200300108A (et) 2005-02-15
BR0113980A (pt) 2003-06-24
NZ524803A (en) 2004-09-24
ATE318822T1 (de) 2006-03-15
EP1319007A1 (en) 2003-06-18
AU6994301A (en) 2002-04-02
KR100765670B1 (ko) 2007-10-10
GEP20074144B (en) 2007-07-10
NO20031266D0 (no) 2003-03-19
AR035340A1 (es) 2004-05-12
SK4982003A3 (en) 2004-05-04
PL361707A1 (en) 2004-10-04
MY138531A (en) 2009-06-30
HRP20030305B1 (en) 2007-12-31
WO2002024702A1 (en) 2002-03-28
US20040176324A1 (en) 2004-09-09
UY26808A1 (es) 2002-01-31
IS6750A (is) 2003-03-18
EP1319007B9 (en) 2007-10-10
MXPA03002412A (es) 2004-05-05
UA78686C2 (en) 2007-04-25
HRP20030305A2 (en) 2005-04-30

Similar Documents

Publication Publication Date Title
HRP20030305B9 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
HU229457B1 (en) Fungicidal n2-phenylamidine derivatives, intermediates and use thereof
ES2168953A1 (es) Derivados de oxima y su uso como acidos latentes
HRP20020175B1 (hr) N-heterociklički derivati kao inhibitori nos
NO990227L (no) Heterocykliske forbindelser som farmas°ytika
MXPA03004958A (es) Sales onio y su uso como acidos latentes.
MY203593A (en) Polycyclic pyridone derivative
MXPA02001473A (es) Azaindoles que tienen afinidad con el receptor de serotonina.
MXPA02012569A (es) Ftalidas substituidas novedosas, un procedimiento para su preparacion y las composiciones farmaceuticas que contienen a las mismas.
CO4970802A1 (es) Compuesto bencimidazol-5 sustituido con estabilidad mejorada
GB1087243A (en) Improvements in or relating to naphthalene derivatives and the manufacture thereof
ES475635A1 (es) Procedimiento para preparar derivados de imidazol.
DK0988312T3 (da) 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose
ES471239A1 (es) Un metodo para la produccion de compuestos de tiazolidina
UA43338C2 (uk) Похідні бензолу
ES2111448B1 (es) Composiciones de revestimiento en polvo.
MY131141A (en) N-benzyl-indoles, processes for their preparation and pharmaceutical compositions containing them.
ES8200113A1 (es) Un procedimiento para la preparacion de derivados de cefalosporina.
ES2140393T3 (es) Compuestos de penem.
SE7412163L (cg-RX-API-DMAC7.html)
DE69217148D1 (de) Isoxazole derivate als lichtschutzmittel
DK113180A (da) Fremgangsmaade til fremstilling af derivater af dithiepino (1,4) (2,3-c) pyrrol
DE60007984D1 (de) Antioxidantien, verfahren zu ihrer herstellung und ihre verwendungen
KR950000638A (ko) 3, 4-디히드록시칼콘 유도체
BR0013100A (pt) Processo para a preparação de um composto de 2-arilvinil alquil éter

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
B9IS Complete republication of an hr-b document
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090610

Year of fee payment: 9

PBON Lapse due to non-payment of renewal fee

Effective date: 20100621